|Articles|May 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
IND Submitted for CYT-500
Cytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer.
Advertisement
PRINCETON, New JerseyCytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer. CYT-500 targets prostate-specific membrane antigen (PSMA), which is abundantly expressed on the surface of prostate cancer cells. The agent incorporates the same monoclonal antibody used in Cytogen's ProstaScint (capromab pendetide) molecular imaging agent but is linked to a therapeutic payload.
Articles in this issue
over 20 years ago
Genentech Files sBLA for Avastin for First-Line NSCLC Treatmentover 20 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaover 20 years ago
New Imaging, ChemoRT Recommendations From NCCNover 20 years ago
Panitumumab Improves PFS in Advanced Colon Caover 20 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsover 20 years ago
Growing Evidence Supports Stem Cell Hypothesis of Cancerover 20 years ago
FDA Approves New Every-3-Week Dosing for Aranespover 20 years ago
Telephone Often Delivers News of Breast Cancer DiagnosisAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
4
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
5